Products

OphtAI
OphtAI
Clinical Decision Support & Reference
OphtAI is an AI platform that analyzes retinal photos to detect the main pathological risks to the retina, including Diabetic Retinopathy, Glaucoma, and AMD, providing real-time analysis and detailed PDF reports.

See all 1 product →

About OphtAI

OphtAI is a French healthcare AI company specializing in artificial intelligence for ophthalmology. It was formed as a joint venture between Evolucare, a key player in hospital IT systems, and ADCIS, an expert in image analysis. The company’s solutions are designed to assist ophthalmology professionals in addressing the increasing demands of patient care, including a wider range of activities and diseases, and a growing number of patients requiring follow-up, care, or screening. OphtAI’s technology aims to optimize organizational workflows and enhance diagnostic performance, allowing specialists to focus on complex cases and high-value activities while ensuring widespread and safe screening.

For physicians, OphtAI offers a CE-marked medical device that provides semi-automated screening and grading of various retinal pathologies. The AI analyzes retinal images to detect conditions such as diabetic retinopathy (DR), diabetic macular edema, glaucoma, and age-related macular degeneration (AMD). The system provides rapid, computer-aided diagnoses with explicable results through lesion mapping and confidence indexes. It also includes features like real-time image quality checks to avoid re-examinations, automated preliminary patient sorting based on criticality, and automated patient record filling. OphtAI’s solutions are compatible with standard field color retinographs and can be integrated into existing IT tools and teleophthalmology platforms, facilitating collaboration among healthcare professionals and streamlining workflows. The company emphasizes that its AI does not replace clinicians but enhances their capabilities, reducing the risk of error, identifying early warning signs, and improving clinical decision-making.

Focus Areas

Artificial Intelligence Ophthalmology Diabetic Retinopathy Glaucoma Age-related Macular Degeneration Retinal Image Analysis Medical Device Tele-ophthalmology Screening Diagnosis

Business Intelligence

PartnershipsOptomed, Topcon Healthcare, iCare (Revenio Group Corporation), AP-HP, INSERM, LATIM
TechnologyCloud-native (Microsoft Azure), Deep Learning, AI operating system (integrated with various fundus cameras and ophthalmology software)

What Physicians Need to Know

Specialization in Retinal Pathologies
OphtAI specializes in the detection of major retinal pathologies, including Diabetic Retinopathy (DR), Glaucoma, and Age-related Macular Degeneration (AMD). They aim to expand this to around 40 pathologies and additional pathological signs.
AI-Powered Image Analysis
Their core offering is an AI solution that analyzes retinal photos captured with standard color retinographs to detect pathological risks in real-time.
High Diagnostic Performance
OphtAI boasts high sensitivity (up to 99%) and specificity (87%) in detecting retinal conditions, with performance comparable to human experts.
Rapid Screening and Diagnosis
The system provides results in seconds, significantly faster than traditional methods, and generates detailed PDF reports.
Medical Device Certification
OphtAI is a CE-marked medical device (Class IIa) and is working towards FDA certification, ensuring regulatory compliance and reliability.
Tele-ophthalmology and Remote Screening
The solution supports tele-ophthalmology, enabling large-scale automated screening and making eye care more accessible, especially in resource-limited settings.
Automated Workflow Integration
OphtAI can be accessed via a web browser, a desktop application, or through an API for integration into existing healthcare software, streamlining workflows and reducing repetitive tasks.
Focus on Diabetic Retinopathy
OphtAI has demonstrated superior sensitivity in detecting Diabetic Retinopathy, even outperforming human screeners in some studies, and can assess diabetic macular edema.
Glaucoma and AMD Detection
The platform also effectively screens for Glaucoma and Age-related Macular Degeneration (AMD), including early forms like Age-related Maculopathy.
Physician Tip

OphtAI's AI-powered retinal image analysis offers ophthalmologists and other eye care professionals a powerful tool to enhance diagnostic accuracy, improve screening efficiency, and optimize patient management. The system's high sensitivity and rapid analysis can aid in early detection of critical pathologies like Diabetic Retinopathy, Glaucoma, and AMD, allowing for timely intervention and potentially preventing vision loss. Its ability to provide detailed reports with lesion localization and confidence scores can support clinical decision-making. Furthermore, the tele-ophthalmology capabilities and integration options can help extend screening reach, particularly in underserved areas, and streamline workflows by automating initial image review and patient prioritization. This allows specialists to focus on complex cases and higher-value activities, ultimately improving the overall quality and accessibility of eye care. It's important to remember that AI is a tool to augment, not replace, clinical expertise.

OphtAI offers flexible integration options, including a web-based platform (OphtAI WEB), a desktop application (OphtAI APP), and an API for seamless integration into partners' software offerings. They are compatible with standard field color retinographs and have established partnerships for integration with various ophthalmology software and data management platforms like Topcon Harmony, Icare, CrystalVue, Area, Oplus, Optomed, Teo, and UmamiView. This allows for automated analysis of photos added to a PC directory and the automatic generation of PDF reports, directly within existing clinical workflows.

Products by OphtAI

1 product in the directory

OphtAI
OphtAI
Clinical Decision Support & Reference
OphtAI is an AI platform that analyzes retinal photos to detect the main pathological risks to the retina, including Diabetic Retinopathy, Glaucoma, and AMD, providing real-time analysis and detailed PDF reports.

What the Web Says

OphtAI is a company specializing in artificial intelligence (AI) for ophthalmology, focusing on the early detection and screening of retinal pathologies like diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD). Their AI algorithms analyze retinal images, aiming to improve diagnostic performance, optimize medical resources, and enhance patient adherence to care pathways. The company's solutions are CE-marked and have shown promising results in scientific studies, with ongoing efforts for FDA approval.

Overall: Positive

Strengths

  • High diagnostic performance comparable to human experts
  • Automated initial review of images and sorting by urgency, saving time for medical staff
  • Ability to integrate with existing IT tools and fundus cameras
  • Potential to reduce screening costs per patient
  • Provides consistent and detailed feedback with data like predictive values and heat maps
  • Fast processing time (less than 1 second per image)

Limitations

  • Limited publicly available product reviews on major platforms like G2, Capterra, and Reddit.
  • Lack of specific company/employer reviews on platforms like Glassdoor.
  • Some AI health tools in general are marketed with high expectations that don't always align with reality.
  • Integration could be smoother for some AI tools.
  • Some AI tools lack sufficient documentation and onboarding.

Based on reviews from: OphtAI : AI for ophthalmologists, PR Harmony and OphtAI - Topcon Healthcare, A scoping review of artificial intelligence as a medical device for ophthalmic image analysis in Europe, Australia and America - PMC, OPHTAI CONFIRMS ITS UNRIVALED PERFORMANCE AND EFFICIENCY IN A REAL-WORLD VALIDATION STUDY PUBLISHED IN THE ADA DIABETES CARE JOU - Evolucare, OphtAI: Proactive Eye Care, Now Possible, OphthoACR (Ophthalmology Automated Chart Review): An AI-Powered Tool for Complete Automation of Ophthalmology Chart Reviews and Cohort Data Analysis - PMC, Ophthalmology-Cloud Software Pricing, Alternatives & More 2026 | Capterra, Capterra Reviews & Ratings 2026 - TrustRadius, Tried a few AI health tools but still confused which one actually works - Reddit, Optux AI Reviews 2026: Details, Pricing, & Features - G2, Optivate Reviews 2026: Details, Pricing, & Features - G2, Best Optometry Software for Small Business in 2026 | G2, Optosys Reviews 2026: Details, Pricing, & Features - G2, Working at OPTO INTERNATIONAL: Employee Reviews | Indeed.com, Capterra Pros and Cons | User Likes & Dislikes - G2, Is capterra good? - Quora, G2: Business Software and Services Reviews, Working at Ophthalmic: Employee Reviews | Indeed.com, Working at Ophthalmic Tech: Employee Reviews | Indeed.com, Working at Opya, Inc. in San Jose, CA: Employee Reviews | Indeed.com, Do any of you use the Ottai CGM? : r/diabetes_t1 - Reddit, Ovatu Reviews 2026. Verified Reviews, Pros & Cons - Capterra, Working at Opya, Inc.: Employee Reviews about Culture | Indeed.com, Read Customer Service Reviews of optavia.com - Trustpilot

Last updated: 2026-06-21

Videos

News, demos, and interviews about OphtAI.

Loading videos...

Videos load interactively. If none appear, search YouTube for OphtAI →

View all on YouTube

Press & Coverage

PRNewswire
Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond
Optain Health, a healthcare technology company utilizing AI, robotic retinal imaging, and teleophthalmology for early disease detection, announced the close of an oversubscribed $26 million Series A funding round. The funding will accelerate the global rollout of Optain's platform, which uses oculomics to detect eye and systemic diseases.
2025-09
OphtAI
OphtAI at SANTEXPO 2026: AI for visual screening
OphtAI will be exhibiting at the SANTEXPO trade fair in Paris from May 19-21, 2026, showcasing their artificial intelligence solution for retinal condition screening. The company is a solution developed by the French group Evolucare Technologies.
2026-04
OphtAI
OphtAI : AI for ophthalmologists
This article discusses how AI is transforming ophthalmology, with solutions like OphtAI achieving high performance in analyzing retinal images for early detection of chronic conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration. It highlights the organizational impact of AI in automating initial image review and prioritizing cases.
2026-03
OphtAI
Evolucare OphtAI CE certified according to the MDR
OphtAI, a medical AI solution in ophthalmology, has received CE certification according to the European Medical Devices Regulation 2017/745, underscoring its safety and reliability.
2025-12
OphtAI
OphtAI at the Heart of the Artificial Intelligence Revolution in Ophthalmology
Alexandre Le Guilcher, Research & Innovation Director of Evolucare Technologies, discusses OphtAI's role as a pioneer in healthcare IT systems, leveraging AI for ophthalmology. OphtAI was created in partnership with AP-HP and its Ophdiat network to detect retinal pathologies.
2025-08
OphtAI
OphtAI at the SFO 2025 Congress: spotlight on ophthalmological AI
OphtAI will be present at the Congress of the French Ophthalmology Society (SFO) from May 10-12, 2025, to showcase its AI solution for ophthalmological screening. The solution will be enhanced with new clinical indicators and a new user experience called MyOphtAI.
2025-04
Topcon Healthcare
Topcon Healthcare and OphtAI Announce their Partnership in EMEA
Topcon Healthcare and OphtAI announced a partnership to integrate OphtAI's AI algorithm into Topcon's Harmony Referral System in EMEA. This integration provides eye care professionals with smarter access to AI services for detecting eye pathologies like diabetic retinopathy, macular edema, glaucoma, and AMD.
2023-02
PMC (PubMed Central)
Towards population-independent, multi-disease detection in fundus photographs - PMC
This peer-reviewed article discusses the generalizability of deep learning algorithms for screening various ocular anomalies in fundus photographs, with OphtAI being cited as one of the automated DR screening algorithms implemented as a clinical device.
2023-07

Frequently Asked Questions

OphtAI specializes in AI solutions for analyzing retinal images. Their primary focus is on detecting and characterizing diabetic retinopathy, glaucoma, and age-related macular degeneration (AMD) to aid in early screening and diagnosis.
OphtAI's technology is designed for seamless integration into current tele-ophthalmology platforms. It typically requires digital retinal images, which can be uploaded to their AI analysis system, providing rapid results to support remote diagnosis and patient management.
OphtAI's solutions are developed with a strong emphasis on regulatory compliance. They have obtained CE marking as a class IIa medical device in Europe, and are actively pursuing FDA clearance in the United States.
OphtAI's AI algorithms have undergone rigorous validation processes, demonstrating high accuracy in detecting and classifying diabetic retinopathy, glaucoma, and AMD. Their performance is often benchmarked against expert human graders to ensure reliability and clinical utility.
OphtAI typically offers flexible pricing models that can be adapted to the scale of implementation, from individual clinics to large healthcare networks. Their packages usually include technical support, software updates, and ongoing assistance to ensure optimal performance and user satisfaction.
OphtAI actively collaborates with various partners, including leading ophthalmology clinics, research institutions, and technology providers. These partnerships aim to further validate their AI solutions, expand their reach, and integrate their technology into broader healthcare ecosystems.
OphtAI is committed to long-term growth and innovation in the AI healthcare sector. They are backed by strategic investments and have a clear roadmap for expanding their product offerings and market presence, ensuring stability and continuous development in the dynamic field of ophthalmic AI.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.